

## Immunomodulatory Medications

---

Reference Number: RDF2205-24

Date of Response: 23/01/24

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

**1. How many patients has your trust/health board treated in the past 6 months (for any disease) with the following drugs:**

Answer: Please see table below. In accordance with Section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles. In these cases  $\leq 5$  is used to indicate that a figure between 1 and 5 is being suppressed.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and should not be published.

<b>Drug Name</b>	<b>Patient Count</b>
Aubagio (teriflunomide)	68
Avonex (interferon beta-1a)	28
Betaferon (interferon beta-1b)	$\leq 5$
Brabio (glatiramer acetate)	Nil
Copaxone (glatiramer acetate)	31
Extavia (beta interferon-1b)	Nil
Gilenya (fingolimod)	$\leq 5$
Lemtrada (alemtuzumab)	$\leq 5$
Kesimpta (ofatumumab)	65
Mavenclad (cladribine)	21
Mayzent (siponimod)	8
Ocrevus (ocrelizumab)	43
Plegridy (peginterferon beta-1a)	28
Ponvory (ponesimod)	$\leq 5$
Rebif (beta interferon-1a)	16
Tecfidera (dimethyl fumarate)	128
Tysabri (natalizumab)	11
Tysabri (natalizumab) pre-filled syringes ONLY	37
Vumerity (diroximel fumarate)	$\leq 5$
Zeposia (ozanimod)	$\leq 5$

2. *How many patients are registered with your trust/health board for the following conditions:*

Answer: Please see table below representing the last six months July 2023 to December 2023.

<i>MS (any type*)</i>	<i>RRMS</i>	<i>PPMS</i>	<i>SPMS</i>
610	334	63	119

*[\*] Excludes any of the other MS diagnosis listed*

